All In Biotech

Drug Trial Radar · NCT02198378

Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.

Analgesia of Acute Coronary Syndromes With ST-segment Elevation in a Pre-hospital Setting. Randomized Non-inferiority Trial of the Association MEOPA + Paracetamol Versus Morphine.

Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

680

Actual

Start

Nov 2014

Primary completion

Jan 2017

Study completion Jan 2017

Sponsor

Lead sponsor
University Hospital, ToulouseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In the management of acute coronary syndromes with ST-segment elevation (STEMI), early analgesia reduces the effects of hyperadrenalism which increases the size of myocardial infarction. In order to reduce pain intensity, the recommendations advocate emergency use of morphine. In STEMI patients, other analgesic treatments could provide analgesia that is at least as effective as morphine. The equimolar oxygen/nitrous oxide mixture (MEOPA) is widely used in emergency medicine and has minor secondary effects that are very rapidly reversible when inhalation is discontinued. Used in association with paracetamol, it could be an at least equally effective alternative to the use of morphine.

Conditions

  • Acute Coronary Syndrome

Interventions

  • MEOPA and paracetamolDrug

    The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.

  • MorphineDrug

    Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN\> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effective analgesia (NRS score≤ 3) at 30 minutes after the start of analgesiaTime frame: 30 minutes after randomisation.

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier d'Agen

    Agen, France

  • Centre Hospitalier Jean Minjoz

    Besançon, France

  • CHU Avicenne

    Bobigny, France

  • Hôpital Pellegrin

    Bordeaux, France

  • Centre Hospitalier Bourg-en-Bresse

    Bourg-en-Bresse, France

  • Centre Hospitalier de Chambéry

    Chambéry, France

  • Centre Hospitalier Louis Pasteur

    Chartres, France

  • Centre Hospitalier Chateauroux

    Châteauroux, France

  • CHU d'Estaing

    Clermont-Ferrand, France

  • Centre Hospitalier Beaujon

    Clichy, France

  • Centre Hospitalier Alpes Léman

    Contamine-sur-Arve, France

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France

  • Centre Hospitalier Dijon

    Dijon, France

  • Centre Hospitalier du Val d'Ariège

    Foix, France

  • Centre Hospitalier Raymond Poincaré

    Garches, France

  • Centre Hospitalier de Grenoble

    Grenoble, France

  • Centre Hospitalier Départemental La Roche/Yon

    La Roche-sur-Yon, France

  • CHRU Lille

    Lille, France

  • CHU Dupuytren

    Limoges, France

  • Centre Hospitalier Edouard Herriot

    Lyon, France

  • Centre Hospitalier de la Timone

    Marseille, France

  • Centre Hospitalier Marc Jacquet

    Melun, France

  • CHR Bon Secours

    Metz, France

  • CHRU Montpellier

    Montpellier, France

  • CHU Nancy

    Nancy, France

  • CHU Nantes

    Nantes, France

  • Centre Hospitalier de Nice

    Nice, France

  • Centre Hospitalier Necker

    Paris, France

  • Centre Hospitalier Pitié-Salpétrière

    Paris, France

  • Groupe hospitamier Lariboisière-Fernand Widal-St-Louis

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • Centre Hospitalier René Dubos

    Pontoise, France

  • Centre Hospitalier Annecy-Gennevois

    Pringy, France

  • Centre Hospitalier Comminges Pyrénées

    Saint-Gaudens, France

  • Centre Hospitalier Poulon la Seyne-sur-mer

    Toulon, France

  • CHU Toulouse

    Toulouse, France

  • CHRU Tours

    Tours, France

  • Centre Hospitalier de Valence

    Valence, France

  • Centre Hospitalier Lucien Hussel

    Vienne, France

  • CHU Félix Guyon

    Saint-Denis, Reunion

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.